EAM
ABUS icon

Exome Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Exome Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$340K Hold
75,484
– – 0.18% 54
2025
Q4 		$363K Hold
75,484
– – 0.17% 59
2025
Q3 		$343K Hold
75,484
– – 0.21% 62
2025
Q2 		$233K Buy
+75,484
New +$251K 0.17% 60
2025
Q1 		– Sell
-28,300
Closed -$92.5K – 60
2024
Q4 		$92.5K Buy
+28,300
New +$104K 0.07% 59

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Exome Asset Management's ABUS Position: Q1 2026 in Review

Exome Asset Management held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 75,484 shares worth $340K. The position accounts for 0.18% of the portfolio, ranked #54.

Exome Asset Management first reported a position in ABUS in Q4 2024 and has held it in 5 quarters since. The position peaked at $363K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Exome Asset Management held 75,484 shares of Arbutus Biopharma worth $340K as of Q1 2026.
  • Exome Asset Management left its Arbutus Biopharma share count unchanged in Q1 2026.
  • Arbutus Biopharma made up 0.18% of Exome Asset Management's portfolio in Q1 2026, its #54 holding.
  • Exome Asset Management first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 5 quarters since.
  • Exome Asset Management's Arbutus Biopharma position peaked at $363K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.